David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
The three claims put forward by Dr. Roger Poisson to rationalize his enrollment of ineligible subjects in clinical trials do not justify research fraud. None the less, certain lessons for the conduct of clinical research can be learned from the affair: experimental therapies should be made available to technically ineligible subjects when no effective therapy exists for their disease; further research must investigate the possible benefits of clinical-trial participation; broadly based, pragmatic trials must be regarded as the ideal model; and each eligibility criterion in a clinical-trial protocol should be justified.
|Keywords||No keywords specified (fix it)|
No categories specified
(categorize this paper)
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library||
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Charles Weijer, Characterizing the Population in Clinical Trials: Barriers, Comparability, and Implications for Review.
Myriam Skrutkowska & Charles Weijer, Do Patients with Breast Cancer Participating in Clinical Trials Receive Better Nursing Care?
Charles Weijer, Selecting Subjects for Participation in Clinical Research: An Empirical Inquiry and Ethical Analysis.
Charles Weijer (1999). Selecting Subjects for Participation in Clinical Research: One Sphere of Justice. Journal of Medical Ethics 25 (1):31-36.
Don Marquis (1989). An Ethical Problem Concerning Recent Therapeutic Research on Breast Cancer. Hypatia 4 (2):140 - 155.
Maurie Markman (2004). The Research Misconception. International Journal of Applied Philosophy 18 (2):241-252.
Charles Weijer, Benjamin Freedman, Stanley Shapiro, Abraham Fuks, Myriam Skrutkowska & Maria Sigurjonsdottir, Assessing the Interpretation of Criteria for Clinical Trial Eligibility: A Survey of Oncology Investigators.
Ana Smith Iltis (2005). Third-Party Payers and the Costs of Biomedical Research. Kennedy Institute of Ethics Journal 15 (2):135-160.
Jerry Menikoff (2006). What the Doctor Didn't Say: The Hidden Truth About Medical Research. Oxford University Press.
Charles Weijer, Benjamin Freedman, Abraham Fuks, James Robbins, Stanley Shapiro & Myriam Skrutkowska, What Difference Does It Make to Be Treated in a Clinical Trial? A Pilot Study.
Abraham Fuks, Charles Weijer, Benjamin Freedman, Stanley Shapiro, Myriam Skrutkowska & Amina Riaz, A Study in Contrasts: Eligibility Criteria in a Twenty-Year Sample of NSABP and POG Clinical Trials.
Lynn A. Jansen (2005). A Closer Look at the Bad Deal Trial: Beyond Clinical Equipoise. Hastings Center Report 35 (5):29-36.
Malcolm G. Booth (2007). Informed Consent in Emergency Research: A Contradiction in Terms. Science and Engineering Ethics 13 (3):351-359.
Added to index2010-09-08
Total downloads4 ( #280,616 of 1,413,285 )
Recent downloads (6 months)2 ( #94,880 of 1,413,285 )
How can I increase my downloads?